Yanxia Shi

1.0k total citations
26 papers, 354 citations indexed

About

Yanxia Shi is a scholar working on Oncology, Surgery and Cancer Research. According to data from OpenAlex, Yanxia Shi has authored 26 papers receiving a total of 354 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 11 papers in Surgery and 10 papers in Cancer Research. Recurrent topics in Yanxia Shi's work include Cancer Immunotherapy and Biomarkers (7 papers), Breast Cancer Treatment Studies (7 papers) and Bladder and Urothelial Cancer Treatments (6 papers). Yanxia Shi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Breast Cancer Treatment Studies (7 papers) and Bladder and Urothelial Cancer Treatments (6 papers). Yanxia Shi collaborates with scholars based in China, United States and Hong Kong. Yanxia Shi's co-authors include Yuchen Cai, Zhongyu Yuan, Roujun Peng, Tao Qin, Shusen Wang, Xiaoyu Teng, Qing Xia, Rongzhen Luo, Wenqi Jiang and Pei‐Yu Huang and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer.

In The Last Decade

Yanxia Shi

24 papers receiving 348 citations

Peers

Yanxia Shi
Gui-Long Guo China
Carina Pereira Portugal
Kaibo Guo China
Masaki Tsujie Japan
Kan Xue China
Junhui Zhao China
Chi-Chung Chan China
Sara A. Väyrynen Finland
Ning‐Ping Zhang China
Gui-Long Guo China
Yanxia Shi
Citations per year, relative to Yanxia Shi Yanxia Shi (= 1×) peers Gui-Long Guo

Countries citing papers authored by Yanxia Shi

Since Specialization
Citations

This map shows the geographic impact of Yanxia Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yanxia Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yanxia Shi more than expected).

Fields of papers citing papers by Yanxia Shi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yanxia Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yanxia Shi. The network helps show where Yanxia Shi may publish in the future.

Co-authorship network of co-authors of Yanxia Shi

This figure shows the co-authorship network connecting the top 25 collaborators of Yanxia Shi. A scholar is included among the top collaborators of Yanxia Shi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yanxia Shi. Yanxia Shi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Yang, Yalan, Haifeng Li, Wei Yang, & Yanxia Shi. (2024). Improving efficacy of TNBC immunotherapy: based on analysis and subtyping of immune microenvironment. Frontiers in Immunology. 15. 1441667–1441667. 4 indexed citations
3.
4.
Wang, Zhi‐Qiang, Yanxia Shi, Yuhong Li, et al.. (2023). A phase II clinical trial of toripalimab in advanced solid tumors with POLE/POLD1 mutation.. Journal of Clinical Oncology. 41(4_suppl). 802–802.
5.
Wei, Xiaoli, Furong Liu, Jihong Liu, et al.. (2022). First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors. Nature Communications. 13(1). 7012–7012. 13 indexed citations
6.
Wang, Kun, Yanxia Shi, Yuanqi Zhang, et al.. (2022). Markers Associated With Tumor Recurrence in Patients With Breast Cancer Achieving a Pathologic Complete Response After Neoadjuvant Chemotherapy. Frontiers in Oncology. 12. 860475–860475. 6 indexed citations
7.
8.
9.
Guo, Shengjie, Yanxia Shi, Xinan Sheng, et al.. (2022). First‐line programmed death receptor‐1 ( PD ‐1) inhibitor and epidermal growth factor receptor (EGFR) blockade, combined with platinum‐based chemotherapy, for stage IV penile cancer. British Journal of Urology. 131(2). 198–207. 11 indexed citations
10.
Niu, Feiyu, et al.. (2021). Urokinase plasminogen activator predicts poor prognosis in hepatocellular carcinoma. Journal of Gastrointestinal Oncology. 12(4). 1851–1859. 7 indexed citations
11.
An, Xin, Xi Lin, Anli Yang, et al.. (2020). Cavin3 Suppresses Breast Cancer Metastasis via Inhibiting AKT Pathway. Frontiers in Pharmacology. 11. 1228–1228. 3 indexed citations
12.
13.
Ye, Yunlin, Xiangdong Li, Shengjie Guo, et al.. (2018). The effects of intra-arterial chemotherapy on bladder preservation in patients with T1 stage bladder cancer. World Journal of Urology. 36(8). 1191–1200. 11 indexed citations
14.
Yang, Hang, Ye Cao, Zhiming Li, et al.. (2018). The role of protein p16INK4a in non‑oropharyngeal head and neck squamous cell carcinoma in Southern China. Oncology Letters. 16(5). 6147–6155. 6 indexed citations
15.
Qin, Tao, Zhongyu Yuan, Roujun Peng, et al.. (2013). Efficacy and Tolerability of Toremifene and Tamoxifen Therapy in Premenopausal Patients with Operable Breast Cancer: A Retrospective Analysis. Current Oncology. 20(4). 196–204. 15 indexed citations
16.
Cai, Yuchen, Qing Xia, Rongzhen Luo, et al.. (2013). Berberine inhibits the growth of human colorectal adenocarcinoma in vitro and in vivo. Journal of Natural Medicines. 68(1). 53–62. 61 indexed citations
17.
Xue, Cong, Xi Wang, Roujun Peng, et al.. (2012). Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China. Cancer Science. 103(9). 1679–1687. 53 indexed citations
18.
19.
Wang, Shusen, Yanxia Shi, Zhongyu Yuan, et al.. (2011). Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens. Medical Oncology. 29(2). 547–553. 13 indexed citations
20.
Peng, Roujun, Shusen Wang, Yanxia Shi, et al.. (2011). Patients 35 years old or younger with operable breast cancer are more at risk for relapse and survival: A retrospective matched case–control study. The Breast. 20(6). 568–573. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gui-Long Guo Breakdown of academic impact, for papers by Carina Pereira Breakdown of academic impact, for papers by Kaibo Guo Breakdown of academic impact, for papers by Masaki Tsujie Breakdown of academic impact, for papers by Kan Xue Breakdown of academic impact, for papers by Junhui Zhao Breakdown of academic impact, for papers by Chi-Chung Chan Breakdown of academic impact, for papers by Sara A. Väyrynen Breakdown of academic impact, for papers by Ning‐Ping Zhang
Rankless by CCL
2026